Solid Biosciences (NASDAQ:SLDB) Price Target Raised to $20.00

Solid Biosciences (NASDAQ:SLDB) had its target price raised by HC Wainwright from $16.00 to $20.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Solid Biosciences’ Q1 2025 earnings at ($0.43) EPS, Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.76) EPS, FY2026 earnings at ($1.99) EPS, FY2027 earnings at ($1.73) EPS, FY2028 earnings at ($0.77) EPS and FY2029 earnings at $1.14 EPS.

Other analysts have also recently issued research reports about the stock. Wedbush began coverage on shares of Solid Biosciences in a report on Friday, December 13th. They set an “outperform” rating and a $16.00 target price on the stock. JMP Securities assumed coverage on Solid Biosciences in a research report on Tuesday, December 10th. They issued an “outperform” rating and a $15.00 price target for the company. Truist Financial assumed coverage on Solid Biosciences in a research report on Wednesday, January 8th. They issued a “buy” rating and a $16.00 price target for the company. Chardan Capital reaffirmed a “buy” rating and issued a $16.00 price target on shares of Solid Biosciences in a research report on Friday, March 7th. Finally, Citizens Jmp raised Solid Biosciences to a “strong-buy” rating in a research report on Tuesday, December 10th. Nine equities research analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Solid Biosciences has an average rating of “Buy” and an average target price of $15.80.

Solid Biosciences Trading Up 2.1 %

Shares of SLDB stock opened at $5.73 on Monday. Solid Biosciences has a 12 month low of $2.88 and a 12 month high of $15.05. The stock has a market cap of $437.31 million, a PE ratio of -1.88 and a beta of 1.98. The company’s fifty day moving average price is $4.12 and its 200-day moving average price is $5.47.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SLDB. China Universal Asset Management Co. Ltd. bought a new position in Solid Biosciences in the 4th quarter worth approximately $34,000. Corton Capital Inc. bought a new position in shares of Solid Biosciences during the 4th quarter valued at approximately $41,000. Invesco Ltd. bought a new position in shares of Solid Biosciences during the 4th quarter valued at approximately $49,000. Sei Investments Co. bought a new position in shares of Solid Biosciences during the 4th quarter valued at approximately $52,000. Finally, Wells Fargo & Company MN boosted its position in shares of Solid Biosciences by 29.4% during the 4th quarter. Wells Fargo & Company MN now owns 13,138 shares of the company’s stock valued at $53,000 after acquiring an additional 2,986 shares during the last quarter. 81.46% of the stock is currently owned by institutional investors.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.